carmustine has been researched along with Multiple Organ Failure in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Multiple Organ Failure: A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papadakis, V | 1 |
| Dunkel, IJ | 1 |
| Cramer, LD | 1 |
| Kramer, E | 1 |
| Papadopoulos, E | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Willoughby, M | 1 |
| Baker, D | 1 |
| Garvin, J | 1 |
| Strandjord, S | 1 |
| Coccia, P | 1 |
| Kaplan, AM | 1 |
| Klemperer, M | 1 |
| Finlay, JL | 1 |
1 other study available for carmustine and Multiple Organ Failure
| Article | Year |
|---|---|
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2000 |